Hydroxyurea Medac

Hydroxycarbamide, the active ingredient in Hydroxyurea Medac, is an antimetabolite (ribonucleotide reductase inhibitor) presented as an oral tablet for systemic use. It is employed in the management of several hematologic malignancies and sickle cell disease, targeting abnormal cell proliferation.

GNH USA supplies Hydroxyurea Medac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Hydroxyurea acts on malignant and abnormal hematopoietic cells, providing disease‑modifying benefits in several conditions. - Chronic myelogenous leukemia: reduces leukemic cell proliferation and disease burden. - Sickle cell disease: decreases frequency of vaso‑occlusive crises and improves hemoglobin levels. - Essential thrombocythemia: lowers platelet counts and reduces thrombotic risk. - Polycythemia vera: controls red‑cell mass and mitigates splenomegaly. - Melanoma: used as part of combination regimens to inhibit tumor growth.

Hydroxyurea may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Myelosuppression: decreased white blood cells, red blood cells, and platelets. - Gastrointestinal upset: nausea, vomiting, and diarrhea. - Skin changes: hyperpigmentation or rash. - Alopecia: hair thinning or loss. - Mild fever or malaise.

Serious or Rare Side Effects: - Severe bone‑marrow failure requiring transfusion. - Hepatic toxicity: elevated liver enzymes or hepatitis. - Renal impairment: increased creatinine or renal failure. - Life‑threatening cutaneous reactions such as Stevens‑Johnson syndrome. - Acute tumor lysis syndrome. - Severe infection due to profound neutropenia.

Hydroxyurea requires careful monitoring and patient education before and during therapy. - Baseline blood counts: obtain CBC with differential prior to initiation. - Ongoing hematologic monitoring: repeat CBC weekly to monthly as directed. - Renal and hepatic function: assess serum creatinine and liver enzymes regularly. - Pregnancy and lactation: avoid use unless benefits outweigh potential fetal risk. - Contraindications: do not use in patients with known hypersensitivity to hydroxycarbamide. - Store at room temperature: keep in the original container, protect from moisture and heat.

Hydroxyurea can interact with several drug classes, altering efficacy or safety.

Major Interactions (Avoid): - Concurrent myelosuppressive agents (e.g., cytarabine, azacitidine): may cause profound bone‑marrow suppression. - Live vaccines: reduced immune response and risk of infection. - Zidovudine (AZT): additive hematologic toxicity.

Moderate Interactions (Monitor Closely): - NSAIDs and aspirin: increase risk of gastrointestinal bleeding. - Allopurinol: may potentiate cytopenias. - Penicillins and cephalosporins: occasional additive marrow effects. - Antifungal azoles: may affect hydroxyurea metabolism.